Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro can affect the gallbladder. Gallbladder-related problems — including gallstones and gallbladder inflammation — are listed as known side effects of tirzepatide in its UK prescribing information, and the same pattern is recognised across the GLP-1 class of medicines. They are not common, but they are real, and knowing what to watch for matters. As a prescription-only medicine, Mounjaro is dispensed through clinical assessment; a prescriber will weigh your individual risk profile, including any history of gallbladder disease, before treatment begins. This page covers what the evidence says, how to recognise symptoms that need prompt attention, and what the broader picture looks like for people using tirzepatide for weight management.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The link between Mounjaro and gallbladder problems has two distinct threads, and understanding both helps put the risk in perspective.
First, GLP-1 receptor agonists slow gastric emptying and affect gut motility more broadly. That slowing extends to the biliary system: the gallbladder empties less frequently, and when bile sits still for longer, cholesterol crystals have more opportunity to form into stones. You can read more about how this plays out in practice on our page about Mounjaro and the gallbladder.
Second, losing weight quickly (whether through medicine, surgery or a very low-calorie diet) independently increases gallstone risk. When fat stores break down rapidly, the liver secretes more cholesterol into bile than the gallbladder can flush out efficiently. Because tirzepatide can produce substantial weight loss over a relatively short period, the two mechanisms can act together.
The NHS patient information for tirzepatide lists gallbladder disorders among the known side effects. The formal prescribing information classifies cholelithiasis (gallstones) as uncommon, meaning it affects somewhere between 1 in 100 and 1 in 1,000 people taking the medicine, not negligible, but not a reason to avoid treatment without first discussing your individual situation with a prescriber.
People with a prior history of gallstones, a family history of gallbladder disease, or conditions such as haemolytic anaemia that already raise gallstone risk deserve particular attention during the consultation stage.
Most people on Mounjaro will not develop a gallbladder problem. However, the symptoms of gallstones or cholecystitis (inflammation of the gallbladder) can escalate quickly once they start, so recognising them early is genuinely important.
The classic pattern of biliary colic is a cramping or steady pain in the upper-right side of the abdomen, often starting an hour or two after eating a fatty meal. The pain may radiate to the right shoulder or between the shoulder blades. It usually passes within a few hours. If it does not settle, or if it is accompanied by fever, chills, yellowing of the skin or whites of the eyes (jaundice), or persistent vomiting, that picture suggests something more serious, such as an obstructed bile duct or acute cholecystitis.
Those more serious symptoms need same-day assessment, either via your GP urgently or, if the pain is severe and you cannot get through, via 111 or A&E. Do not assume it will pass on its own, and do not simply adjust your Mounjaro dose without speaking to your prescriber first. Our page on gallbladder pain and Mounjaro goes into symptom patterns in more detail.
You can also report any suspected side effect from tirzepatide, including gallbladder symptoms, to the MHRA through the Yellow Card scheme. Patient reports through that system feed directly into ongoing safety monitoring of medicines in the UK.
Mounjaro's most talked-about side effects are gastrointestinal: nausea, bloating, constipation, loose stools, excessive burping. Because upper-abdominal discomfort is also a common GI complaint on tirzepatide, there is a real risk that early gallbladder symptoms get written off as ordinary stomach trouble.
The distinguishing features matter. Ordinary nausea on Mounjaro tends to arrive soon after an injection or after eating too quickly, feels diffuse, and usually settles within a day or two. Gallbladder pain tends to be more localised to the upper right, more intense, and connected specifically to fatty food rather than to the injection schedule. If you notice that pattern, treat it as a separate signal worth investigating rather than an expected part of treatment.
Our fuller guide to Mounjaro side effects covers the complete range, including the GI symptoms and how to manage them alongside treatment. For a closer look at the mechanism driving these issues, the page on why tirzepatide causes gallbladder issues is worth reading.
Keeping your Mounjaro pen stored correctly also supports consistent dosing; the pen lives in the fridge door and is taken out shortly before your weekly injection, temperature excursions can affect the medicine, and any disruption to your dosing routine is worth flagging to your prescriber.
The appropriate response to gallbladder risk is not to avoid Mounjaro, but to go into treatment informed and with a prescriber who knows your history. A pre-existing gallbladder condition is one of the factors a clinician will ask about during assessment; it does not automatically rule out treatment, but it does shape how closely you will be monitored and what symptoms you should report immediately.
At nume, our prescribers review every consultation personally on the same day. If you have questions about gallbladder risk, your history of abdominal surgery, or any other aspect of tirzepatide safety, those are exactly the questions to raise. Check your eligibility and start your free consultation to speak with our clinical team.
For context on the full range of what tirzepatide offers as a treatment, including its licence, trial evidence and what treatment involves, the Mounjaro overview is a good starting point. If cost is a consideration, our Mounjaro pricing page explains what is included in a private prescription through a regulated UK pharmacy.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.